BACKGROUND: The Easyhaler® device-metered dry powder inhaler containing Salmeterol and Fluticasone propionate (S/F) has been developed for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD). We report two studies which evaluated the in vitro flow rate dependence of delivered dose (DD) and fine particle dose (FPD) of S/F Easyhaler versus Seretide Diskus®. METHODS: A randomized controlled trial (RCT) assessed inspiratory flow parameters of S/F Easyhaler and Seretide Diskus in subgroups of patients with asthma (children, adolescents and adults, and elderly) and in COPD patients. The 10th, 50th, and 90th percentile airflow rates were determined and utilized in vitro, to evaluate flow rate dependence of DD and FPD. Flow rate dependence was evaluated relative to the result obtained at the 50th percentile and any values deviating from 100% indicated flow rate dependence. The volumetric flow rate dependence (Q) index derived from FPD at 10th and 90th percentile airflows was also evaluated. RESULTS: Overall, 227 patients were enrolled and randomized; 216 completed the RCT. In total, 55.5% of patients were female, and the mean age was 46.3 years. Clinically relevant airflow rates (46, 68, and 85 L/min for S/F Easyhaler and 44, 71, and 96 L/min for Seretide Diskus) were carried forward into the in vitro study, which demonstrated similar flow rate dependence of DD and FPD for S/F Easyhaler compared with Seretide Diskus; all values were within ±15% limits across the 10th, 50th, and 90th percentile airflow rates. Q index results suggested that both S/F Easyhaler and Seretide Diskus are medium airflow-dependent products. CONCLUSIONS: Similar in vitro flow rate dependence of DD and FPD was demonstrated for S/F Easyhaler compared with Seretide Diskus, across a range of clinically relevant airflow rates, collected from patients with asthma and COPD.
RCT Entities:
BACKGROUND: The Easyhaler® device-metered dry powder inhaler containing Salmeterol and Fluticasone propionate (S/F) has been developed for the treatment of patients with asthma and chronic obstructive pulmonary disease (COPD). We report two studies which evaluated the in vitro flow rate dependence of delivered dose (DD) and fine particle dose (FPD) of S/F Easyhaler versus Seretide Diskus®. METHODS: A randomized controlled trial (RCT) assessed inspiratory flow parameters of S/F Easyhaler and Seretide Diskus in subgroups of patients with asthma (children, adolescents and adults, and elderly) and in COPDpatients. The 10th, 50th, and 90th percentile airflow rates were determined and utilized in vitro, to evaluate flow rate dependence of DD and FPD. Flow rate dependence was evaluated relative to the result obtained at the 50th percentile and any values deviating from 100% indicated flow rate dependence. The volumetric flow rate dependence (Q) index derived from FPD at 10th and 90th percentile airflows was also evaluated. RESULTS: Overall, 227 patients were enrolled and randomized; 216 completed the RCT. In total, 55.5% of patients were female, and the mean age was 46.3 years. Clinically relevant airflow rates (46, 68, and 85 L/min for S/F Easyhaler and 44, 71, and 96 L/min for Seretide Diskus) were carried forward into the in vitro study, which demonstrated similar flow rate dependence of DD and FPD for S/F Easyhaler compared with Seretide Diskus; all values were within ±15% limits across the 10th, 50th, and 90th percentile airflow rates. Q index results suggested that both S/F Easyhaler and Seretide Diskus are medium airflow-dependent products. CONCLUSIONS: Similar in vitro flow rate dependence of DD and FPD was demonstrated for S/F Easyhaler compared with Seretide Diskus, across a range of clinically relevant airflow rates, collected from patients with asthma and COPD.
Authors: L Pekka Malmberg; Mark L Everard; Jussi Haikarainen; Satu Lähelmä Journal: J Aerosol Med Pulm Drug Deliv Date: 2014-06-30 Impact factor: 2.849
Authors: Omar Sharif Usmani; Federico Lavorini; Jonathan Marshall; William Christopher Nigel Dunlop; Louise Heron; Emily Farrington; Richard Dekhuijzen Journal: Respir Res Date: 2018-01-16
Authors: Henry Chrystyn; Job van der Palen; Raj Sharma; Neil Barnes; Bruno Delafont; Anadi Mahajan; Mike Thomas Journal: NPJ Prim Care Respir Med Date: 2017-04-03 Impact factor: 2.871
Authors: Merja Kirjavainen; Leena Mattila; Mikko Vahteristo; Jani Korhonen; Satu Lähelmä Journal: J Aerosol Med Pulm Drug Deliv Date: 2018-03-01 Impact factor: 2.849
Authors: Mark L Levy; Will Carroll; José L Izquierdo Alonso; Claus Keller; Federico Lavorini; Lauri Lehtimäki Journal: Adv Ther Date: 2019-09-02 Impact factor: 3.845
Authors: L Pekka Malmberg; Anna S Pelkonen; Ville Vartiainen; Mikko Vahteristo; Satu Lähelmä; Rain Jõgi Journal: J Thorac Dis Date: 2021-02 Impact factor: 3.005
Authors: Adolfo Baloira; Araceli Abad; Antonia Fuster; Juan Luis García Rivero; Patricia García-Sidro; Eduardo Márquez-Martín; Marta Palop; Néstor Soler; J L Velasco; Fernando González-Torralba Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-04-19
Authors: Rain Jõgi; Leena Mattila; Mikko Vahteristo; Aino Takala; Satu Lähelmä; Ville A Vartiainen; Ari Lindqvist Journal: Int J Chron Obstruct Pulmon Dis Date: 2021-04-30